{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:45:06Z","timestamp":1785393906990,"version":"3.55.0"},"reference-count":80,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Synovial sarcoma (SyS) is a rare aggressive soft tissue sarcoma carrying the chromosomal translocation t(X;18), encoding the fusion transcript SS18::SSX. The fusion oncoprotein interacts with both BAF enhancer complexes and polycomb repressor complexes, resulting in genome-wide epigenetic perturbations and a unique altered genetic signature. Over 80% of the patients are initially diagnosed with localized disease and have a 5-year survival rate of 70\u201380%, but metastatic relapse occurs in 50% of the cases. Advanced, unresectable, or metastatic disease has a 5-year survival rate below 10%, representing a critical issue. This review summarizes the molecular mechanisms behind SyS and illustrates current treatments in front line, second line, and beyond settings. We analyze the use of immune check point inhibitors (ICI) in SyS that do not behave as an ICI-sensitive tumor, claiming the need for predictive genetic signatures and tumor immune microenvironment biomarkers. We highlight the clinical translation of innovative technologies, such as proteolysis targeting chimera (PROTAC) protein degraders or adoptive transfer of engineered immune cells. Adoptive cell transfer of engineered T-cell receptor cells targeting selected cancer\/testis antigens has shown promising results against metastatic SyS in early clinical trials and further improvements are awaited from refinements involving immune cell engineering and tumor immune microenvironment enhancement.<\/jats:p>","DOI":"10.3390\/cancers15153887","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T01:48:50Z","timestamp":1690768130000},"page":"3887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-8118","authenticated-orcid":false,"given":"Lorena","family":"Landuzzi","sequence":"first","affiliation":[{"name":"Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-720X","authenticated-orcid":false,"given":"Maria Cristina","family":"Manara","sequence":"additional","affiliation":[{"name":"Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-4953","authenticated-orcid":false,"given":"Laura","family":"Pazzaglia","sequence":"additional","affiliation":[{"name":"Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1702-4108","authenticated-orcid":false,"given":"Pier-Luigi","family":"Lollini","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology and Biology of Metastasis, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-9499","authenticated-orcid":false,"given":"Katia","family":"Scotlandi","sequence":"additional","affiliation":[{"name":"Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Picci, P., Manfrini, M., Fabbri, N., Gambarotti, M., and Vanel, D. (2014). Atlas of Musculoskeletal Tumors and Tumorlike Lesions: The Rizzoli Case Archive, Springer International Publishing.","DOI":"10.1007\/978-3-319-01748-8"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/curroncol28030177","article-title":"Synovial Sarcoma: A Clinical Review","volume":"28","author":"Gazendam","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fonc.2019.01078","article-title":"Epigenetic Targets in Synovial Sarcoma: A Mini-Review","volume":"9","author":"Hale","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.02.002","article-title":"Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity","volume":"58","author":"Vlenterie","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2004.11.093","article-title":"Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis","volume":"22","author":"Guillou","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/PAS.0000000000001447","article-title":"A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma","volume":"44","author":"Baranov","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Landuzzi, L., Ruzzi, F., Lollini, P.L., and Scotlandi, K. (2023). Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. Cancers, 15.","DOI":"10.3390\/cancers15030588"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1158\/2159-8290.CD-20-1219","article-title":"A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11912-020-00985-w","article-title":"Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes","volume":"22","author":"Rassy","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","article-title":"The epigenomics of sarcoma","volume":"20","author":"Nacev","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41556-018-0221-1","article-title":"A non-canonical SWI\/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation","volume":"20","author":"Michel","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41580-021-00341-1","article-title":"The roles of Polycomb repressive complexes in mammalian development and cancer","volume":"22","author":"Piunti","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ccell.2018.05.002","article-title":"The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma","volume":"33","author":"McBride","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e202000808","DOI":"10.26508\/lsa.202000808","article-title":"The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies","volume":"4","author":"Boulay","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1914291","DOI":"10.1080\/23723556.2021.1914291","article-title":"HDAC2 links ubiquitination to tumor suppression in synovial sarcoma","volume":"8","author":"Cooley","year":"2021","journal-title":"Mol. Cell. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2012.01.010","article-title":"Deconstruction of the SS18-SSX fusion oncoprotein complex: Insights into disease etiology and therapeutics","volume":"21","author":"Su","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/1078-0432.CCR-10-2050","article-title":"Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis","volume":"17","author":"Ito","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbrc.2013.01.003","article-title":"Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells","volume":"432","author":"Hayakawa","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2159-8290.CD-14-1246","article-title":"Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy","volume":"5","author":"Nielsen","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_20","first-page":"1011","article-title":"PTEN and other tumor suppressor gene mutations as secondary genetic alterations in synovial sarcoma","volume":"11","author":"Saito","year":"2004","journal-title":"Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.1066","article-title":"APC mutations in synovial sarcoma","volume":"196","author":"Saito","year":"2002","journal-title":"J. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2559.2010.03626.x","article-title":"Mutational analysis of E-cadherin, beta-catenin and APC genes in synovial sarcomas","volume":"57","author":"Subramaniam","year":"2010","journal-title":"Histopathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/stem.452","article-title":"Synovial sarcoma is a stem cell malignancy","volume":"28","author":"Naka","year":"2010","journal-title":"Stem Cells"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100402","DOI":"10.1016\/j.esmoop.2022.100402","article-title":"Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): Real-life data from the French Sarcoma Group (FSG)","volume":"7","author":"Campion","year":"2022","journal-title":"ESMO Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.2217\/fon-2022-0348","article-title":"Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond)","volume":"18","author":"Carroll","year":"2022","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2217\/fon-2022-0477","article-title":"Treatment patterns and outcomes in metastatic synovial sarcoma: A real-world study in the US oncology network","volume":"18","author":"Pokras","year":"2022","journal-title":"Future Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes","volume":"12","author":"Schoffski","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejca.2022.07.010","article-title":"New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC\u2014Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas","volume":"174","author":"Kantidakis","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study","volume":"23","author":"Supko","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","article-title":"A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas","volume":"48","author":"Cresta","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/CAD.0000000000000228","article-title":"Trabectedin in advanced synovial sarcomas: A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network","volume":"26","author":"Sanfilippo","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: A randomised, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11864-023-01056-5","article-title":"Relapsed Synovial Sarcoma: Treatment Options","volume":"24","author":"Weiss","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fonc.2019.00955","article-title":"Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.suronc.2018.07.012","article-title":"Neutrophil\/lymphocyte ratio is associated with survival in synovial sarcoma","volume":"27","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fausti, V., De Vita, A., Vanni, S., Ghini, V., Gurrieri, L., Riva, N., Casadei, R., Maraldi, M., Ercolani, G., and Cavaliere, D. (2023). Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte\/Monocyte Ratio and Trabectedin. Cancers, 15.","DOI":"10.3390\/cancers15041080"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.05.008","article-title":"Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma","volume":"99","author":"Brodowicz","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","article-title":"Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy","volume":"40","author":"Wanior","year":"2021","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-021-00647-8","article-title":"Molecular mechanisms underpinning sarcomas and implications for current and future therapy","volume":"6","author":"Damerell","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.05.018","article-title":"Vorinostat in refractory soft tissue sarcomas\u2014Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO)","volume":"64","author":"Schmitt","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bjc.2013.442","article-title":"A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group","volume":"109","author":"Cassier","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: An international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1123464","DOI":"10.3389\/fonc.2023.1123464","article-title":"Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma","volume":"13","author":"Fuchs","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41591-020-01212-6","article-title":"Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma","volume":"27","author":"Neftel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled analysis of phase II trials","volume":"13","author":"Italiano","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11015","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts","volume":"37","author":"Burgess","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"168145","DOI":"10.1155\/2013\/168145","article-title":"A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma","volume":"2013","author":"Maki","year":"2013","journal-title":"Sarcoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: A single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.20.03452","article-title":"Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1","volume":"40","author":"Chawla","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/s41467-022-30874-8","article-title":"Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma","volume":"13","author":"Richards","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-21-3445","article-title":"Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma","volume":"28","author":"Klemen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gordon, E.M., Chawla, S.P., Tellez, W.A., Younesi, E., Thomas, S., Chua-Alcala, V.S., Chomoyan, H., Valencia, C., Brigham, D.A., and Moradkhani, A. (2023). SAINT: A Phase I\/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. Cancers, 15.","DOI":"10.3390\/cancers15030906"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1150765","DOI":"10.3389\/fonc.2023.1150765","article-title":"New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas","volume":"13","author":"Seong","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: A phase 2 PEMBROSARC trial cohort","volume":"28","author":"Italiano","year":"2022","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.omto.2021.12.007","article-title":"A novel immune-related gene signature predicting survival in sarcoma patients","volume":"24","author":"Ren","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1158\/1078-0432.CCR-20-0832","article-title":"HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome","volume":"26","author":"Rosenbaum","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ijc.1451","article-title":"Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen NY-ESO-1 but not MAGE-A1 or CT7","volume":"94","author":"Jungbluth","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma","volume":"8","author":"Melchiori","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.34453","article-title":"A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma","volume":"152","author":"Ishihara","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/hupa.2002.31295","article-title":"MAGE antigen expression in monophasic and biphasic synovial sarcoma","volume":"33","author":"Antonescu","year":"2002","journal-title":"Hum. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1682381","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: A phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11562","DOI":"10.1200\/JCO.2022.40.16_suppl.11562","article-title":"Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (\u201cAfami-cel\u201d [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid\/round cell liposarcoma phase 1 and phase 2 trials","volume":"40","author":"Attia","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.1200\/JCO.2021.39.15_suppl.11504","article-title":"SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma","volume":"39","author":"Tine","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e1507600","DOI":"10.1080\/2162402X.2018.1507600","article-title":"PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy","volume":"7","author":"Luk","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"A1009","DOI":"10.1136\/jitc-2021-SITC2021.959","article-title":"959\u2005Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses\u2014Clinical update on the ACTengine\u00ae IMA203 trial","volume":"9","author":"Wermke","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref_80","first-page":"A325","article-title":"298 Final analysis of the phase 1 trial of NY-ESO-1\u2013specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)","volume":"8","author":"Demetri","year":"2020","journal-title":"J. ImmunoTher. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:22:40Z","timestamp":1760127760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":80,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153887"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153887","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]}}}